Arsenic trioxide-induced cardiotoxicity: insights into the oxidative stress-inflammation positive feedback loop, translational biomarkers and targeted cardioprotective strategies— a narrative review
Year: 2026
Type: review
Abstract: Arsenic trioxide (ATO) is a first-line chemotherapeutic agent that achieves a complete remission rate above 90% in newly diagnosed acute promyelocytic leukemia, with indications expanding to multiple hematological malignancies and solid tumors. However, dose-dependent cardiotoxicity-manifesting as acute QTc prolongation and malignant arrhythmia, as well as chronic myocardial hypertrophy, interstitial fibrosis and progressive heart failure-remains a critical clinical barrier that limits its therapeutic window, and no approved targeted cardioprotective regimens are currently available in clinical practice. This narrative Mini Review proposes an integrated mechanistic framework centered on the oxidative stress-inflammation positive feedback loop, which complements the conventional view of two independent pathogenic pathways. In this framework, ATO-induced mitochondrial dysfunction and impaired Nrf2 antioxidant defense initiate oxidative stress as the upstream trigger; ROS subsequently drives inflammatory activation via NF-κB and NLRP3 inflammasome pathways, while sustained inflammation in turn aggravates oxidative damage by suppressing Nrf2 activity and disrupting mitochondrial homeostasis. This proposed self-amplifying loop exhibits spatiotemporal heterogeneity. It appears incompletely established in acute electrophysiological injury, but may serve as a potential mechanistic contributor to chronic structural remodeling. Based on this framework, this work summarizes dual-target cardioprotective strategies that preserve ATO's anti-tumor efficacy, and evaluates translational biomarkers for early risk stratification. Collectively, this review provides a mechanistic foundation for precision cardioprotection and clinical safety optimization of ATO-based chemotherapy.
Source: Frontiers in Oncology
Authors: Haiyan Wu, Jian Lv, Xiaoyang Hu
Institution: Heilongjiang University of Chinese Medicine
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Award: G5605370143
OpenAlex ID: W7221535373
